Vista

Refine Clinical Development Strategies

Access a multi-indication oncology dataset based on EMR data that offers comprehensive insights into the full range of oncological diseases, revealing unmet epidemiological needs and providing a holistic understanding of patient journeys at scale.

Group 46
Use Cases

Track Holistic Patient Journeys at Scale

Vista allows life sciences to holistically track the journeys of real oncology patients across the disease spectrum. The inclusion of non-oncological data enables further identification of epidemiological trends and guidance of research decisions.

Automated Updates and Data Standardization

Vista uses structured EMR data and machine learning to standardize patient data across disease states and treatment protocols for easy comparative analysis.

Designed for Large-Scale Biopharmaceutical Research

Vista is continuously being improved and enriched with data and clinical logic through collaboration with biopharma partners.

Group 202

COTA by the Numbers

2.1M+ Cancer Patient Lives

50/50 Academic vs. Community Treatment Setting

3 Approvals Supported

9 Hematology and Solid Tumor Diagnoses

5-Year Average Follow-up

2X Higher Inclusion Percentage in ECA vs. Competitor

Group 203
Additional Support

Get the Most of Your Vista Data with Real-World Insights and Support

Real-World Insights and Support is an optional add-on that pairs perfectly with your Vista data. Our team of clinical experts, researchers, and statisticians will come alongside your teams to help them use the data to design studies, run analyses, and construct regulatory submission packages.

Resources

Fueling the Future of Cancer Research

Explore our collection of clinical research, recent press, podcasts, and more.

Real-world data gets high marks for feasibility in lung cancer research: A cross-industry collaboration is advancing RWD

The real world is an unpredictable place.  It can be messy and confusing, full of challenges and uncertainties that have...

Light the Night: Bringing hope to patients during Blood Cancer Awareness Month

September is Blood Cancer Awareness Month, a time to bring extra attention to the more than 1.6 million people living...

COTA and Panalgo Q&A

COTA Spokesperson: C.K. Wang, Chief Medical Officer Panalgo Spokesperson: Meg Richards, PhD, MPH, Executive Director of Scientific Strategy Abbreviated answers...

See the Bigger Picture of Oncology

Discover the power of real-world cancer data to help you understand patient journeys across the oncology spectrum and inform research directions.

Group 11